HeartBeam, Inc. (BEAT), a Santa Clara, California-based medical technology company developing cable-free, ambulatory electrocardiogram (ECG) solutions for cardiac monitoring outside a medical setting, trades near $0.41, roughly 90% below its 52-week high. The shares remain the subject of a small and increasingly stale set of analyst price targets. The central question is whether BEAT can climb back toward a $4.00 stock price target.
Four current, identifiable analyst price targets were reviewed. The low is $2.00 from Maxim Group, which initiated coverage with a Buy in July 2026. The high is $5.00, held by both StoneX (reiterated Buy in August 2026) and Benchmark (which lowered its target from $8 in May 2026). B. Riley Securities set a $4.00 target in March 2026. The arithmetic mean is $4.00, within a wide $2.00-to-$5.00 range.
The picture is unusually fragmented. H.C. Wainwright lowered its target to $2.50 in May 2026 and then downgraded the stock to Neutral in September 2026, effectively removing its price objective, while D. Boral Capital downgraded to Hold in April 2026. Some aggregators report an average closer to $3.50 based on a different, smaller subset of targets. Because most targets substantially predate the stock's collapse and have not yet "caught up" to it, they should be read as indicative rather than precise. Bullish analysts emphasize the long-term remote cardiac monitoring opportunity; cautious voices point to slower commercial traction and dilution.
The latest verified price is about $0.41, with a market capitalization near $23 million. Reaching the $4.00 central target would require a gain of roughly 875%, which is a very large move. HeartBeam remains development-stage and loss-making, with negative earnings per share (EPS). Its most recent quarterly results showed a net loss in the low-teens millions of dollars, narrowing modestly year-over-year, and the company completed an equity raise at $0.80 per share in 2026 to extend its funding runway. The 52-week range of $0.355 to $4.00 underscores both the depth of the decline and the fact that the stock has already traded at the target level within the past year.
The technical backdrop is notably weak. The $4.00 central target coincides with the stock's 52-week high, a level that now functions as major resistance and a prior breakdown point. Support sits near the $0.355-to-$0.40 zone around the 52-week low, with psychological levels at $0.50 and $1.00 in between. The long-term trend remains firmly negative, and the stock would need to reclaim progressively higher levels with sustained volume before any credible recovery toward the target could unfold.
Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon for each BEAT report is not always disclosed and can vary. Investors should monitor upcoming quarterly results and guidance, any new or revised funding arrangements, FDA and commercial launch milestones, and analyst target revisions. Given the divergence between the share price and the remaining targets, fresh analyst commentary will be especially informative.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like BEAT, these signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual review. Explore AI Daily Buy/Sell Signals to see how automated analysis can complement your own research.
The $4.00 central target is the average of four identifiable analyst price targets spanning $2.00 to $5.00, but it reflects a valuation framework established largely before HeartBeam's roughly 90% decline. The required move of about 875% is very large, and the stock's development-stage status, recurring dilution, and already-softening analyst sentiment present serious obstacles. On the other side, an FDA-cleared product, an extended funding runway, and a narrowing loss provide a foundation. Whether the target is reachable depends on tangible commercial traction and funding stability; no outcome is guaranteed, and the wide analyst range signals genuine disagreement about the company's trajectory.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BEAT has been loosely correlated with SNOW. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BEAT jumps, then SNOW could also see price increases.
| Ticker / NAME | Correlation To BEAT | 1D Price Change % | ||
|---|---|---|---|---|
| BEAT | 100% | -10.94% | ||
| SNOW - BEAT | 37% Loosely correlated | -5.13% | ||
| APPN - BEAT | 33% Poorly correlated | +1.61% | ||
| MNDY - BEAT | 32% Poorly correlated | +3.23% | ||
| ZS - BEAT | 31% Poorly correlated | -5.29% | ||
| CRM - BEAT | 31% Poorly correlated | -1.47% | ||
More | ||||
| Ticker / NAME | Correlation To BEAT | 1D Price Change % |
|---|---|---|
| BEAT | 100% | -10.94% |
| Services to the Health Industry industry (41 stocks) | -1% Poorly correlated | -3.31% |
| Health Services industry (238 stocks) | -41% Negatively correlated | -2.69% |